Journal of Vaccines & Vaccination

HIV Vaccines Research & Development: Progress and Challenges

Pan Yingje^* Department of Bioinformatics and Biostatistics, Shanghai Jiao Tong University, Shanghai, China
^*Correspondence: Pan Yingje, Department of Bioinformatics and Biostatistics, Shanghai Jiao Tong University, Shanghai, China, Email:

Received: 01-Mar-2025, Manuscript No. JVV-25-29303; Editor assigned: 03-Mar-2025, Pre QC No. JVV-25-29303; Reviewed: 17-Mar-2025, QC No. JVV-25-29303; Revised: 21-Mar-2025, Manuscript No. JVV-25-29303; Published: 28-Mar-2025, DOI: 10.35248/2157-7560.25.16.592

Description

Human Immunodeficiency Virus (HIV) continues to pose a major global public health threat, with millions of individuals affected worldwide. While significant strides have been made in the management of HIV through Antiretroviral Therapy (ART), which suppresses viral replication and enables people living with HIV to lead longer, healthier lives, the ultimate goal remains the development of a preventive vaccine. Such a vaccine holds the potential not only to reduce new infections but also to eventually bring the HIV epidemic under control. Despite decades of research, however, creating an effective HIV vaccine has proven to be one of the most complex challenges in modern medicine [1-2].

HIV is a retrovirus that attacks the bodyâ??s immune system, specifically targeting CD4+ T cells. The gradual loss of these cells leads to immune system failure and the progression to Acquired Immunodeficiency Syndrome (AIDS) if left untreated. Although ART has transformed HIV from a fatal disease to a manageable chronic condition, it does not cure the infection. Furthermore, access to ART remains unequal across different regions of the world, particularly in resource-limited settings, underlining the importance of preventive strategies such as vaccination [3-4].

A preventive HIV vaccine would ideally provide long-term protection, reduce the need for lifelong medication and curb transmission rates. However, several scientific and biological factors have made vaccine development particularly difficult. One of the greatest challenges is the virus's high genetic variability. HIV mutates rapidly and exists in multiple subtypes and circulating strains across different geographical regions. This genetic diversity means that a vaccine must be effective against a broad range of viral variants, which significantly complicates its design.

In addition to its diversity, HIV has evolved sophisticated strategies to evade the human immune system. The virus can shield its vulnerable components using a dense layer of sugars, known as the glycan shield, which makes it difficult for antibodies to bind and neutralize the virus. HIV can also integrate into the hostâ??s genome and remain hidden in latent reservoirs, avoiding detection by the immune system. Unlike many other viruses, there are no known cases of natural immunity to HIV. Most people infected with the virus eventually develop AIDS without treatment, providing no clear immune model for vaccine development to follow [5].

Despite these hurdles, researchers have made substantial progress in recent years. Several vaccine approaches are currently under investigation. Preventive vaccines, which aim to prime the immune system to recognize and attack HIV before it establishes infection, have been at the forefront. Viral vector vaccines, which use harmless viruses to deliver HIV genes and elicit immune responses, were tested in the RV144 trial in Thailand. Though the trial only demonstrated modest protection, it provided the first evidence that a vaccine could reduce HIV risk. More recently, mRNA vaccine technology, which was rapidly advanced during the COVID-19 pandemic, is being applied to HIV. These vaccines can be quickly adapted to target various HIV strains and early-phase trials are underway. Protein subunit vaccines, another approach, utilize purified HIV proteins to stimulate immune responses, often with the help of immuneboosting adjuvants [6].

Therapeutic vaccines are also being studied, targeting individuals already infected with HIV. These vaccines are designed to enhance immune control of the virus, reduce dependence on ART and potentially eliminate latent viral reservoirs. One promising area of research is the study of broadly Neutralizing Antibodies (bNAbs), which have the ability to neutralize a wide array of HIV strains. Scientists are working to design vaccines that can induce the production of such antibodies in the body, which could offer broad and long-lasting protection.

Additional innovations include mosaic vaccines, which use genetic elements from multiple HIV strains to provoke a broader immune response. Trials such as Imbokodo and Mosaico have been launched to evaluate the efficacy of these candidates. Though some studies, like HVTN 702 in South Africa, have been halted due to lack of efficacy, each trial contributes critical insights that refine future strategies. Advances in immunogen design, powered by breakthroughs in structural biology, are also allowing scientists to craft HIV proteins with precision, targeting parts of the virus that are most vulnerable to immune attack [7-8].

None of this progress would be possible without strong international collaboration. HIV vaccine development is a global effort that brings together scientists, clinicians, pharmaceutical companies, governments and philanthropic organizations. Initiatives such as the Global HIV Vaccine Enterprise, alongside sustained funding from bodies like the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation, play a pivotal role in supporting research and clinical trials.

Conclusion

In summary, although an effective HIV vaccine remains elusive, there is justified optimism grounded in ongoing scientific advancements. Continued investment in understanding the virus, improving vaccine technologies and strengthening global partnerships will be essential. A successful HIV vaccine, when combined with current prevention and treatment tools such as PrEP and ART, has the potential to transform global health and bring us closer to ending the HIV epidemic once and for all.

References

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, etâ?¯al. Vaccination with ALVAC and AIDSVAX to prevent HIVâ??1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.

   [Crossref] [Google Scholar] [PubMed]

2. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai Phaseâ?¯III HIVâ??1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015;66:423–437.

   [Crossref] [Google Scholar] [PubMed]

3. Sadanand S, Suscovich TJ, Alter G. Broadly neutralizing antibodies against HIV: new insights to inform vaccine design. Annu Rev Med. 2016;67:185-200.

   [Crossref] [Google Scholar] [PubMed]

4. Ahmad M, Ahmed OM, Schnepp B, Johnson PR. Engineered expression of broadly neutralizing antibodies against human immunodeficiency virus. Annu Rev Virol. 2017;4:491-510.

   [Crossref] [Google Scholar] [PubMed]

5. McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 2017;275:11–20.

   [Crossref] [Google Scholar] [PubMed]

6. Gilbert PB, Juraska M, deCamp AC. Immuneâ??correlates analysis of an HIVâ??1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-1286.

   [Crossref] [Google Scholar] [PubMed]

7. Kim H, Haynes BF. Broadly neutralizing macaque monoclonal antibody against the HIVâ??1 V3â??glycan patch. eLife. 2020;9:e61991.

   [Crossref] [Google Scholar] [PubMed]

8. Gaudinski MR, Houser KV, Doriaâ??Rose NA. Safety and pharmacokinetics of broadly neutralizing human monoclonal antibody VRC07â??623LS in healthy adults. Lancet HIV. 2019;6(10):e667-e679.

   [Crossref] [Google Scholar] [PubMed]